期刊文献+

肾病患者心脏自主神经功能变化的临床研究 被引量:1

下载PDF
导出
摘要 目的 了解肾功能正常之肾病者和尿毒症病人心脏自主神经 (CAN)功能的变化 ,及血透对尿毒症者CAN功能的影响。方法 对 3 0例肾功能正常的肾病者 (A组 )、3 0例正常人 (C组 )和 3 0例尿毒症者 (B组 )血透前、后的 5 2 0次窦性心搏 ,应用短时心率变异 (HRV)的时域、频域及非线性分析方法 ,评价CAN功能状态。结果 B组者血透前、后时域指标RR间期平均值 (MRR)、全部正常窦性心搏间期 (NN)的标准差 (SDNN)、相邻NN间期差值的均方根 (rMSSD)、相邻NN间期相差大于 5 0ms占心动周期数的百分比 (PNN50 )、心率变异指数 (HRVI)和频域指标极低频 (VLF)、低频 (LF)、高频 (HF)、总功率 (TP)均显著低于A组和C组 (P<0 0 0 1)。A组HRVI、VLF、LF、HF、TP显著低于C组 ( P <0 0 5 )。LF HF在各组间无显著性差异 ( P >0 0 5 )。血透前、后上述各项指标均无显著差异 ( P>0 0 5 )。尿毒症者Poincare散点图呈点状 ,正常对照组和肾病组则呈慧星状。结论 慢性肾病者在肾功能正常期已出现CAN功能损伤 ,尿毒症者更甚。
机构地区 南京军医学院第
出处 《实用心电学杂志》 2001年第1期7-8,共2页 Journal of Practical Electrocardiology
  • 相关文献

参考文献9

  • 1[1]Task force of ESC and NASPE. Heart rate variability: Standards of mea srement physiological interpretation and clinical use. Circulation, 1996,93(5) :1043 ~ 1065
  • 2[2]Barron HV, Lesh MD, san francisco F, et al. Autonomic nervous system and sudden cardiac death. JACC, 1996,27:1053~ 1060
  • 3[3]Toyry JP, Niskanen LK, Mantysaari MJ, et al. Occnrrence, predictors and clinical significance of autonomic neuropathy in NIDDM, ten - year follow- up from the diagnosis. Diabetes, 1996,45:308 ~ 315
  • 4孙瑞龙,吴宁,杨世豪,陆再英,郭林妮,屈建石,黄永麟,戚文航,蒋文平.心率变异性检测临床应用的建议[J].中华心血管病杂志,1998,26(4):252-255. 被引量:807
  • 5[5]Adamson PB, Wanoli E, lazzara R et al. Short HRV time segnents cor relate to 24 hour Holter HRV. PACE, 1991,14(2) :747 ~ 751
  • 6[6]Malpas SC, Maling TJB. Heart - rate variability and cardiac autononic function in diabetes. Diabetes, 1990,39(6): 1177 ~ 1181
  • 7[7]Kleiger BE, Bigger JT, Bosner MS et al. Stability over time of variables measuring HRV in normal subjects. Am J Cardiol, 1991,68(5) :626 ~631
  • 8[8]Malik M, Camm AJ. Heart rate variability and clinical cardiology. Br Heart J, 1994,71:3~6
  • 9王海燕.肾脏病学.肾病综合征(第2版)[M].北京:人民卫生出版社,1997.1066.

共引文献811

同被引文献20

  • 1叶脉安,黄湖辉,伍卫.尿毒症患者心室晚电位记录的临床意义[J].中国急救医学,1996,16(6):18-20. 被引量:1
  • 2Amann K,Buzello M,Simonaviciene A.Capillary/myocyte mismatch in the heart in renal failure-a role for erythropoietin? Nephrol Dial Transplant,2000,15(7):964
  • 3Cook J.Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vas Biol,2000,20:2032
  • 4Fliser D,Kielstein J,Haller J,et al.Asynnetric dimethylarginine:a cardiovascular risk factor in renal disease?Kidney Int,2003,63(supp184):S37
  • 5Rostand S,Drueke T.Parathyroid hormone,citamin D,and cardiovascular disease in chronic renal failure.Kidney Int,1999,56(2):383
  • 6Gerard M,Sylvain J,Marchais A,et al.Inflammation,arteriosclerosis,and cardiovascular therapy in hemodialysis patients.Kidney Int,2003,63(suppl 84):S88
  • 7Misselwitz J.Advanced glycation end products in children with chronic renal failure and type 1 diabetes.Pediatr Nephrol,2002,17(5):316
  • 8Nalauama M,Kawaguchi Y,Yamada K,et al.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible psthophysiological role in CAPD.Kidney Int,1997,51:182
  • 9Moustapha A,Naso A,Nahlawi M,et al.Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in ESR.Circulation,1998,20:138
  • 10Efendic E,Lindholm B,Bergstrom J,et al.Strong connection between malnutrition,inflammation and arteriosclerosis.Improved treatment of renal failure if underlying factors are attacked.Lakartidningen,1999,96(42):4538

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部